Vidyard is the video platform that helps businesses transform communications and drive more revenue through the strategic use of online video. Going beyond video hosting and management, we help businesses connect with more viewers through interactive and personalized video experiences, learn powerful insights on their viewing audience, turn insights into action with enterprise integrations, and prove the impact of their video programs.

C-Suite On Deck

Tyler Lessard, VP Marketing of Vidyard has been recently named as an Epic Marketer by Marketo. In this interesting Q&A, Tyler takes us through his marketing journey and shares with us the value of technology in an era where videos are not just visually replenishing, but are also empowering the cust...

Events

Related News

GILEAD JOINS GSK, J&J IN OFFERING CORONAVIRUS VACCINE OPTIONS

PharmaTimes | February 05, 2020

news image

With the death toll in China topping 425, the coronavirus, now officially classified as a global health threat by the World Health Organisation (WHO), is showing no signs of slowing down. More than 20,000 cases have been confirmed around the world, with more than 20 nations reporting cases – some involving locals who had not even travelled to China. The pharma industry has been rallying together in a joint effort to develop a vaccine for the virus, which is also known as 2019-nCoV or Wuhan...

Read More

PHARMACY MARKET

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

news image

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More

ALEXION BETS $1.4B ON PORTOLA AND ITS LAGGARD BLEEDING DRUG ANDEXXA

Fiercepharma | May 05, 2020

news image

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...

Read More

VIEWS AND ANALYSIS

CHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR CHILDREN AGED 6 TO 11 YEARS WITH SEVERE ASTHMA WITH TYPE 2 INFLAMMATION

Regeneron Pharmaceuticals, Inc | January 31, 2022

news image

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequate...

Read More
news image

GILEAD JOINS GSK, J&J IN OFFERING CORONAVIRUS VACCINE OPTIONS

PharmaTimes | February 05, 2020

With the death toll in China topping 425, the coronavirus, now officially classified as a global health threat by the World Health Organisation (WHO), is showing no signs of slowing down. More than 20,000 cases have been confirmed around the world, with more than 20 nations reporting cases – some involving locals who had not even travelled to China. The pharma industry has been rallying together in a joint effort to develop a vaccine for the virus, which is also known as 2019-nCoV or Wuhan...

Read More
news image

PHARMACY MARKET

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More
news image

ALEXION BETS $1.4B ON PORTOLA AND ITS LAGGARD BLEEDING DRUG ANDEXXA

Fiercepharma | May 05, 2020

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...

Read More
news image

VIEWS AND ANALYSIS

CHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR CHILDREN AGED 6 TO 11 YEARS WITH SEVERE ASTHMA WITH TYPE 2 INFLAMMATION

Regeneron Pharmaceuticals, Inc | January 31, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequate...

Read More

Resources

Events

C-Suite On Deck

Tyler Lessard, VP Marketing of Vidyard has been recently named as an Epic Marketer by Marketo. In this interesting Q&A, Tyler takes us through his marketing journey and shares with us the value of technology in an era where videos are not just visually replenishing, but are also empowering the cust...